Ultragenyx Pharmaceutical
RARE
309 hedge funds and large institutions have $3.42B invested in Ultragenyx Pharmaceutical in 2025 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 117 increasing their positions, 108 reducing their positions, and 43 closing their positions.
69% more call options, than puts
Call options by funds: $149M | Put options by funds: $87.7M
26% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 43
5% more capital invested
Capital invested by funds: $3.25B → $3.42B (+$169M)
3% more funds holding
Funds holding: 299 → 309 (+10)
2.47% more ownership
Funds ownership: 97.11% → 99.58% (+2.5%)
8% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 108
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$106M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$80.1M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$43.1M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$34.2M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$32.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$22.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$20.8M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$18.1M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$18M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$17.6M |
RARE Hedge Fund Activity: Q2 2025 in Review
309 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2025, worth a combined $3.42B — up 5.2% from $3.25B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new RARE positions and 43 closed out — a net gain of 11 holders — while 117 added to existing stakes and 108 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $106M. The largest seller was Adage Capital Partners, cutting an estimated $22.3M.
- 309 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2025, up from 299 in Q1 2025.
- Funds reported $3.42B of Ultragenyx Pharmaceutical stock for Q2 2025, up 5.2% quarter-over-quarter.
- 54 funds opened new Ultragenyx Pharmaceutical positions in Q2 2025 and 43 closed out, a net change of +11 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2025 was JP Morgan Chase, an estimated $106M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2025 was Adage Capital Partners, an estimated $22.3M sold.
Based on aggregated 13F filings for Q2 2025.